| HealthPartners | Oncology - gene therapy for bladder cancer | 2025-10-01 |
| HealthPartners | Oncology** - denosumab (Prolia® and Xgeva®) – | 2025-10-01 |
| HealthPartners | Oncology ** - denosumab (Prolia®, Xgeva®) | 2025-10-01 |
| HealthPartners | Pompe disease enzyme replacement therapy: | 2025-10-01 |
| HealthPartners | Pompe disease enzyme replacement therapy: | 2025-10-01 |
| HealthPartners | Satralizumab-mwge (Enspryng™) and inebilizumab- | 2025-10-01 |
| HealthPartners | Satralizumab-mwge (Enspryng™) and inebilizumab- | 2025-10-01 |
| HealthPartners | Sebelipase alfa (Kanuma®) | 2025-10-01 |
| HealthPartners | Sebelipase Alfa (Kanuma®) – Minnesota Health Care | 2025-10-01 |
| HealthPartners | Spesolimab-sbzo (Spevigo®) | 2025-10-01 |